Technology
The seal on a vial and the plunger in a syringe are moulded rubber, and rubber is a mixture rather than a material: polymer, filler, curing system and processing aids, any of which can migrate into the medicine it is holding. That is why an apparently trivial component is one of the most tightly controlled things in the plant.
In one sentence
Elastomer components are the moulded rubber parts that seal a drug container — vial stoppers, syringe plungers, needle shields and septa — compounded from halogenated butyl rubber, often barrier-coated, and qualified with the formulation they contact.
Halobutyl rubber is the base polymer because it is exceptionally gas-tight and chemically stable, which is what allows a stopper to hold a sterile product for years and to survive a freeze-dry cycle. The compound around it — fillers, curatives, pigments — is proprietary, and a supplier's formulation catalogue is effectively its product line.
Everything in that compound is a candidate to migrate. Manufacturers therefore run coated components, where a thin fluoropolymer film separates the rubber from the drug, and they specify washing, siliconisation and sterilisation as part of the component rather than as something the filler does afterwards. Ready-to-use components delivered sterile are now the normal purchase.
Two stoppers of the same shape and nominal material can behave completely differently, because what leaches out depends on the recipe and the cure. That is why the qualification names a specific formulation code from a specific supplier, and why second-sourcing a stopper is an extractables and stability programme rather than a purchasing decision.
A fluoropolymer film reduces migration and stops components sticking to each other on a line. Silicone lubricates a plunger so a syringe can be pushed with a usable force, and too little makes the device hard to use while too much appears in the product as particles. Break-loose and glide force are specifications in their own right for a device.
The seal has to hold through freezing, transport, altitude and years of storage, and it is proven by measurement rather than assumed — helium leak or vacuum decay against a defined limit. Cryogenic products push this hardest, because the rubber stiffens far below its normal operating range and the glass and the rubber contract at different rates.
2 of these are marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
What migrates out of the compound and whether the seal holds are both demonstrated per formulation and per storage condition, and that evidence is what fixes the supplier.
The safety case for a compound is a mass spectrometry study of what comes out of it, and the same instruments run the investigation when a particle is found in a vial.
Analytical instrumentsMixing, moulding, washing, siliconising and terminally sterilising components runs on dedicated validated lines, and ready-to-use supply moves that burden from the filler onto the component maker's capacity.
Other pages in this map that name Elastomer components as something they cannot do without.
What each company supplies at this step, and — where a public figure exists — its share of this specific market — with what that share measures, the period it covers and who published it. Some rows also show the company’s own reported revenue for the segment covering this step, which is a different thing: it says how much this business matters to that company, not how much of the market it holds. Not a ranking and not a recommendation.
Supplies the stoppers, plungers and seals most Western injectables are sealed with, including the coated and ready-to-use grades.
The other large elastomer component maker, and the second source most filling sites qualify against.
Supplies elastomer closures and seals alongside the dispensing components they are used with.
Supplies rubber components alongside the glass containers they seal, from one group.
Moulds its own plungers and seals for the syringes and devices it assembles.
Produces the halobutyl polymer the compounds are built on, from a very small number of plants worldwide.
The other producer of halogenated butyl rubber, which is where this chain actually narrows.
Whether ready-to-use sterile component supply keeps pace with new filling capacity.
Whether halobutyl polymer supply becomes visible as a constraint behind the component makers.
Whether cryogenic and frozen products drive changes in compound and seal design.
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.